4D Molecular Therapeutics (NASDAQ:FDMT) announces quarterly earnings results. August 13, 2026 Key points. * 4D Molecular Therapeutics missed earnings expectations: The company reported a quarterly loss of $1.04 per share versus the $1.02 consensus estimate, while revenue of $3.78 million exceeded expectations of $3.62 million. * Shares fell 1.9% to $11.65 after the results. Analysts maintain a "Moderate Buy" consensus rating with an average price target of $29.75, although ratings range from "Strong Buy" to "Sell." * Insiders sold 197,226 shares worth approximately $2.2 million over the past 90 days, while institutional investors own 99.27% of the company's stock. * Five stocks we like better than 4D Molecular Therapeutics. 4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report) posted its quarterly earnings data on Thursday. The company reported ($1.04) earnings per share for the quarter, missing analysts' consensus estimates of ($1.02) by ($0.02), FiscalAI reports. 4D Molecular Therapeutics had a negative net margin of 182.34% and a negative return on equity of 36.83%. The firm had revenue of $3.78 million for the quarter, compared to the consensus estimate of $3.62 million. 4D Molecular Therapeutics stock down 1.9%. NASDAQ:FDMT traded down $0.22 during midday trading on Thursday, hitting $11.65. The stock had a trading volume of 705,798 shares, compared to its average volume of 787,133. 4D Molecular Therapeutics has a one year low of $5.97 and a one year high of $14.00. The company has a market capitalization of $609.06 million, a price-to-earnings ratio of -4.53 and a beta of 2.73. The stock has a 50-day moving average of $10.84 and a 200 day moving average of $9.83. Analyst ratings changes. FDMT has been the subject of a number of recent analyst reports. Chardan Capital raised shares of 4D Molecular Therapeutics to a "strong-buy" rating in a research note on Tuesday, July 28th. Weiss Ratings reissued a "sell (d-)" rating on shares of 4D Molecular Therapeutics in a research note on Friday, July 17th. HC Wainwright restated a "buy" rating and set a $36.00 target price on shares of 4D Molecular Therapeutics in a research report on Monday, July 20th. Wall Street Zen downgraded 4D Molecular Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday, May 9th. Finally, B. Riley Financial initiated coverage on 4D Molecular Therapeutics in a report on Friday, July 31st. They set a "buy" rating and a $37.00 price objective for the company. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, 4D Molecular Therapeutics has a consensus rating of "Moderate Buy" and a consensus target price of $29.75. Insiders place their bets. In other 4D Molecular Therapeutics news, insider Scott Bizily sold 9,810 shares of 4D Molecular Therapeutics stock in a transaction on Tuesday, June 23rd. The stock was sold at an average price of $12.00, for a total transaction of $117,720.00. Following the completion of the sale, the insider directly owned 8,617 shares of the company's stock, valued at $103,404. The trade was a 53.24% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider David Kirn sold 12,415 shares of the company's stock in a transaction on Monday, August 3rd. The stock was sold at an average price of $10.05, for a total value of $124,770.75. Following the completion of the sale, the insider owned 871,737 shares of the company's stock, valued at $8,760,956.85. This represents a 1.40% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 197,226 shares of company stock valued at $2,200,677. 7.90% of the stock is currently owned by corporate insiders. Institutional inflows and outflows. Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Martingale Asset Management L P lifted its holdings in 4D Molecular Therapeutics by 12.4% during the fourth quarter. Martingale Asset Management L P now owns 11,775 shares of the company's stock worth $88,000 after buying an additional 1,303 shares during the period. Commonwealth Equity Services LLC purchased a new position in shares of 4D Molecular Therapeutics in the 4th quarter valued at $150,000. Brevan Howard Capital Management LP purchased a new position in shares of 4D Molecular Therapeutics in the 3rd quarter valued at $143,000. ADAR1 Capital Management LLC bought a new position in shares of 4D Molecular Therapeutics in the 3rd quarter worth $145,000. Finally, Bridgeway Capital Management LLC lifted its stake in shares of 4D Molecular Therapeutics by 100.3% during the 2nd quarter. Bridgeway Capital Management LLC now owns 25,000 shares of the company's stock worth $93,000 after purchasing an additional 12,516 shares during the last quarter. 99.27% of the stock is currently owned by institutional investors. 4D Molecular Therapeutics company profile. 4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches. 4D's pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Continue following MarketBeat Before you consider 4D Molecular Therapeutics, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and 4D Molecular Therapeutics wasn't on the list. While 4D Molecular Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

4D Molecular Therapeutics, a late-stage biotechnology company, has secured a strategic credit facility of up to $200 million from Hercules Capital. The California-based firm focuses on developing durable and disease-targeted therapeutics. The funding agreement was announced on 29 June 2026. No further details about the terms of the credit facility or its intended use were disclosed in the announcement.